Myriad Logo
  • Patients
    • Patient Questions
      • What’s My Risk?
      • How Aggressive is My Disease?
      • How Should I Treat My Disease?
    • Genetic Testing 101
      • Genes & Disease
      • Benefits of Genetic Testing
      • Genetic Testing FAQs
      • Real Patient Stories
    • Patient Resources
      • Hereditary Cancer Risk
      • Women’s Health Resources
      • Depression Resources
      • Oncology Resources
      • Prostate Cancer Resources
      • Patient Record Request
    • Affordability
      • The Myriad Promise
      • Financial Assistance Program
  • Providers
    • Patient Care
      • Predicting Disease
      • Assessing Prognosis
      • Precision Medicine
      • Genetic Testing Process
    • Resources
      • MyriadPro™
      • Order a Test Kit
      • Myriad Lab Certificates
  • Our Tests
    • Myriad’s Tests
      • Hereditary Cancers
        • MyRisk™
      • Breast Cancer
        • EndoPredict®
      • Mental Health
        • GeneSight®
      • Carrier Screen
        • Foresight®
      • Prenatal Screen
        • Prequel®
      • Precision Medicine
        • BRACAnalysis CDx®
        • MyChoice® CDx
        • Precise™ Tumor
      • Prostate Cancer
        • Prolaris®
  • About
    • Company
      • About Myriad Genetics
      • Executive Team
      • Board of Directors
      • Joining the Myriad Team
    • Global Presence
      • Myriad International
      • Myriad Japan
    • Myriad Cares
      • Social Responsibility
      • Patient Advocacy
    • Partnerships
      • Companion Diagnostics
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
    • Divisions
      • Billing
      • Customer Service
      • International
      • Medical Records
      • Medical Services
      • Mental Health
      • Women’s Health
    • Address
      • Myriad Genetics, Inc. 320 Wakara Way Salt Lake City, UT 84108
    • Phone
      • (800) 4-MYRIAD
      • (800) 469-7423
  • Patients
    • Patient Questions
      • What’s My Risk?
      • How Aggressive is My Disease?
      • How Should I Treat My Disease?
    • Genetic Testing 101
      • Genes & Disease
      • Benefits of Genetic Testing
      • Genetic Testing FAQs
      • Real Patient Stories
    • Patient Resources
      • Hereditary Cancer Risk
      • Women’s Health Resources
      • Depression Resources
      • Oncology Resources
      • Prostate Cancer Resources
      • Patient Record Request
    • Affordability
      • The Myriad Promise
      • Financial Assistance Program
  • Providers
    • Patient Care
      • Predicting Disease
      • Assessing Prognosis
      • Precision Medicine
      • Genetic Testing Process
    • Resources
      • MyriadPro™
      • Order a Test Kit
      • Myriad Lab Certificates
  • Our Tests
    • Myriad’s Tests
      • Hereditary Cancers
        • MyRisk™
      • Breast Cancer
        • EndoPredict®
      • Mental Health
        • GeneSight®
      • Carrier Screen
        • Foresight®
      • Prenatal Screen
        • Prequel®
      • Precision Medicine
        • BRACAnalysis CDx®
        • MyChoice® CDx
        • Precise™ Tumor
      • Prostate Cancer
        • Prolaris®
  • About
    • Company
      • About Myriad Genetics
      • Executive Team
      • Board of Directors
      • Joining the Myriad Team
    • Global Presence
      • Myriad International
      • Myriad Japan
    • Myriad Cares
      • Social Responsibility
      • Patient Advocacy
    • Partnerships
      • Companion Diagnostics
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
    • Divisions
      • Billing
      • Customer Service
      • International
      • Medical Records
      • Medical Services
      • Mental Health
      • Women’s Health
    • Address
      • Myriad Genetics, Inc. 320 Wakara Way Salt Lake City, UT 84108
    • Phone
      • (800) 4-MYRIAD
      • (800) 469-7423

News Releases

Jun 23, 2022
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Pipeline
May 03, 2022
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Pipeline
Nov 22, 2021
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
Pipeline
Aug 02, 2021
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Pipeline
May 19, 2021
Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Pipeline
Mar 24, 2021
Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan
Products
Mar 02, 2021
Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services
Pipeline
Feb 12, 2021
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer
Pipeline
Jan 08, 2021
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®
Products
Dec 11, 2020
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations
Pipeline
Nov 16, 2020
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
Pipeline
Nov 11, 2020
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
Pipeline
Oct 16, 2020
German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
Pipeline
Aug 21, 2020
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
Pipeline
Aug 10, 2020
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions
Pipeline
Next page
  • Payers
    • Overview
  • Investors
    • Investor Relations
    • Events & Presentations
  • News
    • Press Releases
    • Myriad Genetics Blog
  • Careers
    • Joining the Team
Myriad Logo

Health. Illuminated.

  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Language Assistance
  • Cookie Preferences
  • © 2022 Myriad Genetics, Inc.